![Pfizer to buy Seagen for $43B to enhance reach of cancer drugs](https://assets2.cbsnewsstatic.com/hub/i/r/2023/03/13/84c98242-be94-4e61-bb30-9bf87851a901/thumbnail/1200x630/d8948e73ae61ec6c21819ed07d10221d/gettyimages-1247595781.jpg)
Pfizer to buy Seagen for $43B to enhance reach of cancer drugs
CBSN
Pfizer will spend $43 billion to buy Seagen and deepen its reach into treating cancer.
The pharmaceutical giant said Monday that it will pay $229 in cash for each Seagen share.
Bothell, Washington-based Seagen Inc. is a biotech drug developer that specializes in antibody-drug conjugate, or ADC, technology. Its key products use lab-made proteins called monoclonal antibodies that seek out cancer cells to help deliver a cancer-killing drug while sparing surrounding healthy tissue.
![](/newspic/picid-6252001-20250211015324.jpg)
As vaccination rates decline, widespread outbreaks of diseases like measles and polio could reemerge
Health officials in western Texas are trying to contain a measles outbreak among mostly school-aged children, with at least 15 confirmed cases. It's the latest outbreak of a disease that had been virtually eliminated in the U.S., and it comes as vaccination rates are declining — jeopardizing the country's herd immunity from widespread outbreaks.